Kang, Sini
Lin, Zhaoyan
Xu, Yang
Park, Minju
Ji, Geun Eog
Johnston, Tony V.
Ku, Seockmo http://orcid.org/0000-0003-2661-5073
Park, Myeong Soo
Funding for this research was provided by:
Collaborative Grant-in-Aid of the HBUT National “111” Center for Cellular Regulation and Molecular Pharmaceutics (XBTK-2021004)
Doctoral start-up fund of Hubei University of Technology (XJ2021000101)
Regional Specialized Industry Development Program (S2848321, S2848321)
Faculty Research and Creative Activity Committee (No. 221745)
Article History
Received: 11 April 2022
Accepted: 26 May 2022
First Online: 7 June 2022
Declarations
:
: Not applicable.
: Not applicable.
: Myeong Soo Park is directly employed by BIFIDO Co., Ltd. and he also hold BIFIDO Co., Ltd stocks as a CTO. Other authors declare no conflicts of interest.